Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 1/20 | 0.72 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.72 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | CDC25B | P30305 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CASP1 | P29466 | 3/20 | 0.43 |
| ▸ | CASP7 | P55210 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.42 |
| ▸ | PRKCH | P24723 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pixantrone SCHEMBL7825 | 1.00 | ECE1 (0.72) | ECE1MUS81KDM4CMAOAMAOB | |
| Pixantrone SCHEMBL17673194 | 0.98 | ECE1 (0.70) | ECE1MUS81KDM4CMAOAMAOB | |
| Pixantrone SCHEMBL7771183 | 0.98 | ECE1 (0.70) | ECE1MUS81KDM4CMAOAMAOB | |
| SCHEMBL28381205 | 0.93 | ECE1 (0.65) | ECE1MUS81KDM4CMAOAMAOB | |
| SCHEMBL29642348 | 0.93 | ECE1 (0.65) | ECE1MUS81KDM4CMAOAMAOB | |
| SCHEMBL28381199 | 0.93 | ECE1 (0.65) | ECE1MUS81KDM4CMAOAMAOB | |
| SCHEMBL28378350 | 0.93 | ECE1 (0.65) | ECE1MUS81KDM4CMAOAMAOB | |
| SCHEMBL13524774 | 0.93 | ECE1 (0.68) | ECE1MUS81KDM4CMAOAMAOB | |
| SCHEMBL29642192 | 0.93 | ECE1 (0.65) | ECE1MUS81KDM4CMAOAMAOB | |
| SCHEMBL29642322 | 0.93 | ECE1 (0.65) | ECE1MUS81KDM4CMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 272 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4232463-B1 | INTERLEUKIN-2-FC FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES INC (US) | 2025-09-03 | — | — | EP | claimed |
| US-20250041208-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2025-02-06 | — | — | US | claimed |
| WO-2024256696-A1 | NEW INJECTABLE PHARMACEUTICAL DEPOT COMPOSITIONS | NANEXA AB (SE) | 2024-12-19 | — | — | WO | claimed |
| EP-4444277-A1 | NEW INJECTABLE COMBINATION FORMULATION | Nanexa AB (SE) | 2024-10-16 | — | — | EP | claimed |
| EP-3661539-B1 | OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | UNIV CALIFORNIA (US) | 2024-10-09 | — | — | EP | claimed |
| WO-2024127018-A1 | NEW INJECTABLE SUSPENSION OF COATED PARTICLES | NANEXA AB (SE) | 2024-06-20 | — | — | WO | claimed |
| EP-4177356-B1 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | PML SCREENING LLC (US) | 2024-05-08 | — | — | EP | claimed |
| EP-3947375-B1 | IMIDAZOLONYLQUINOLINE COMPOUNDS AND THERAPEUTIC USES THEREOF | MERCK PATENT GMBH (DE) | 2024-04-03 | — | — | EP | claimed |
| WO-2023232100-A1 | PHARMACEUTICAL COMBINATION FOR TREATING UTERINE MALIGNANT TUMOR | 正大天晴药业集团股份有限公司 | 2023-12-07 | — | — | WO | claimed |
| EP-3848025-B9 | COMPOSITIONS COMPRISING AMINO ACIDS FOR USE IN THE PREVENTION AND TREATMENT OF CHEMOTHERAPY SIDE EFFECTS | PROFESSIONAL DIETETICS SPA (IT) | 2023-08-16 | — | — | EP | claimed |
| WO-2023105227-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2023-06-15 | — | — | WO | claimed |
| EP-3848025-B1 | COMPOSITIONS COMPRISING AMINO ACIDS FOR USE IN THE PREVENTION AND TREATMENT OF CHEMOTHERAPY SIDE EFFECTS | PROFESSIONAL DIETETICS SPA (IT) | 2023-06-07 | — | — | EP | claimed |
| US-20230082167-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC (US) | 2023-03-16 | — | — | US | claimed |
| EP-3625368-B1 | METHODS FOR ASSESSING THE RISK OF DEVELOPING PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY CAUSED BY JOHN CUNNINGHAM VIRUS BY GENETIC TESTING | PML SCREENING LLC (US) | 2022-11-09 | — | — | EP | claimed |
| US-20220241261-A1 | COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-08-04 | — | — | US | claimed |
| EP-3404118-B1 | METHODS FOR PREDICTING DRUG RESPONSIVENESS IN CANCER PATIENTS | Allarity Therapeutics Europe ApS (DK) | 2022-07-27 | — | — | EP | claimed |
| EP-3426657-B1 | 2 AMINO N [7 METHOXY 2, 3-DIHYDROIMIDAZO-[1, 2-C]QUINAZOLIN-5-YL]PYRIMIDINE 5 CARBOXAMIDES | Bayer Pharma AG (DE) | 2022-07-13 | — | — | EP | claimed |
| EP-3288558-B1 | COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK | Bayer Pharma AG (DE) | 2022-05-11 | — | — | EP | claimed |
| EP-3707261-B1 | FUSION-PROTEINS BASED ON HUMAN FERRITIN AND PROTEASE-CLEAVABLE PEPTIDES AND THEIR USE AS CHEMOTHERAPEUTICS CARRIERS | THENA BIOTECH S R L (IT) | 2022-05-04 | — | — | EP | claimed |
| EP-3373932-B1 | CRYSTALLINE FORM OF A SUBSTITUTED QUINOLINE COMPOUND AND PHARMACEUTICAL COMPOSITIONS THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2022-03-30 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230082167-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | ECE1 1199/4885MUS81 2425/4885KDM4C 3664/4885 |
| US-20220241261-A1 | COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK | IRAK4, IRAK2, IRAK1 | ECE1 2480/4885MUS81 4808/4885KDM4C 1029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.